Top Line: We know from initial reporting of the ADAURA trial that adjuvant osimertinib following resection of EGFR-mutated non-small cell lung cancer (NSCLC) significantly prolongs progression-free survival and reduces the incidence of brain mets.
The Study: As a reminder, 682 patients were randomized after resection of stage IB-IIIA disease to oral osimertinib versus placebo daily for a planned 3 years. This was in addition to any planned chemo at physician discretion (osimertinib, n = 203; placebo, n = 207). Given its dramatic impact on limiting progression, it’s no surprise that final reporting at ASCO this week revealed that adjuvant osimertinib improved 5 year overall survival (88% v 78%). The benefits of osimertinib were seen across subgroups, across stages IB-III, and regardless of the receipt of adjuvant chemotherapy. At the time of final analysis, adjuvant osimertinib more than halved the proportion of patients that experienced disease recurrence (27% v 60%).
TBL:Osimertinib is cemented as a well-tolerated standard of care addition to adjuvant therapy for resected stage IB-IIIA. EGFR-mutant NSCLC with demonstrated improvement in overall survival. | Tsuboi, N Engl J med 2023
The Study: As a reminder, 682 patients were randomized after resection of stage IB-IIIA disease to oral osimertinib versus placebo daily for a planned 3 years. This was in addition to any planned chemo at physician discretion (osimertinib, n = 203; placebo, n = 207). Given its dramatic impact on limiting progression, it’s no surprise that final reporting at ASCO this week revealed that adjuvant osimertinib improved 5 year overall survival (88% v 78%). The benefits of osimertinib were seen across subgroups, across stages IB-III, and regardless of the receipt of adjuvant chemotherapy. At the time of final analysis, adjuvant osimertinib more than halved the proportion of patients that experienced disease recurrence (27% v 60%).
TBL:Osimertinib is cemented as a well-tolerated standard of care addition to adjuvant therapy for resected stage IB-IIIA. EGFR-mutant NSCLC with demonstrated improvement in overall survival. | Tsuboi, N Engl J med 2023